Home / Resources / Videos / ADA 2018 / John Buse Part 1, The Latest Exciting Diabetes Info

John Buse Part 1, The Latest Exciting Diabetes Info




In part 1 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about his excitement over the information presented at the ADA conference about the GLP-1 and SGLT-2 drugs, and how to implement their use.

John Buse, PhD, MD, is professor, chief of the Division of Endocrinology, and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine.

Transcript of this video segment:

Freed:  This is Steve Freed. We’re here at the American Diabetes 78th Association, Scientific Sessions, where all the people that are in the know when it comes to diabetes have to show up to get all the instant news and results of the studies. And today, we have a very special guest, John Buse, who has an illustrious career when it comes to the field of diabetes. Maybe we can start out with, tell us a little bit about your practice and who you are.

Buse: Yeah. I’m an endocrinologist by training. I did an MD PhD in immunology of diabetes and then did my fellowship research in Chicago with Dr. Graeme Bell on the genetics of type 2 diabetes. And pretty much after that I started doing clinical trials. So, the last 25 years I’ve been involved in these large multicenter clinical trials and pharmacoepidemiology type analyses around drug safety and efficacy.

Freed:  So, before we get into the questions regarding why you’re here, with your background and scientific knowledge I always want to ask the question — and that’s one of the great things about what I get to do. I get to find out information before anybody else — what do you think is the greatest information coming out of the ADA at this session?

Buse: Well, I think of the sort of practical information, these new drugs, GLP-1 Receptor Agonists and SGLT2 Inhibitors are extremely exciting. They save lives. We have not had drugs that over short periods of time were associated with reductions in heart attack, strokes, and death, and they improve kidney outcomes. I think that’s the most exciting thing in diabetes in my career. I think the other thing that I try and pay attention to but I haven’t gone to any of the sessions yet is implementation. We have great drugs. We have great devices. We know what needs to be done but somehow as a society we don’t seem to seal the deal. And we need better programs at helping patients adhere to medications, helping patients do the right thing with regards to lifestyle intervention. I think the future is very rosy for folks with diabetes.

Freed:  A cure?

Buse:  A cure — well, for a type 2 diabetes, bariatric surgery is close for many patients. I think, well, I’m very impressed that these GLP-1 Receptor Agonists and SGLT-2 Inhibitors, mixed in with a little metformin and a little insulin, the vast majority of people with diabetes can have their diabetes controlled and  live out normal life expectancies. Not a cure, but really good treatment.

Return to the main page.